Evidence map›Paper›PMID 25231177›Full record

ReviewRheumatology (Oxford, England)2015

Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era.

Dennis McGonagle, Kay-Geert A Hermann, Ai Lyn Tan

Abstract readComparative StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. The Effects ofLife (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. EXPLORing Arthritis with Total-body Positron Emission Tomography.Seminars in musculoskeletal radiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dennis McGonagleLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK and Department of Radiology, Charité Medical School, Berlin, Germany. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK and Department of Radiology, Charité Medical School, Berlin, Germany. d.g.mcgonagle@leeds.ac.uk.
Kay-Geert A HermannLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK and Department of Radiology, Charité Medical School, Berlin, Germany.
Ai Lyn TanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK and Department of Radiology, Charité Medical School, Berlin, Germany. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK and Department of Radiology, Charité Medical School, Berlin, Germany.

Funding

Department of Health NIHR/CS/009/015Wellcome Trust WT 088908/Z/09/Z
6 · The paper itself

Abstract

Rheumatologists have long considered OA and PsA as two completely distinct arthropathies. This review highlights how some forms of generalized OA and PsA may afflict the same entheseal-associated anatomical territories. While degeneration or inflammation may be clearly discernible at the two extremes, there may be a group of patients where differentiation is impossible. Misdiagnosis of a primary degeneration-related pathology as being part of the PsA spectrum could lead to apparent failure of disease-modifying agents, including apparent anti-TNF and apparent IL23/17 axis therapy failure. This is not a reflection of poor clinical acumen, but rather a failure to appreciate that the pathological process overlaps in the two diseases. Whether the category of OA-PsA overlap disease exists or whether it represents the co-occurrence of two common arthropathies that afflict the same anatomical territories has implications for the optimal diagnosis and management of both OA and PsA.

Indexed as

Arthritis, PsoriaticBiological ProductsDiagnosis, DifferentialDisease ManagementHumansMagnetic Resonance ImagingOsteoarthritisPhenotypeRheumatic DiseasesTreatment OutcomeBiological Productsenthesitisosteoarthritispathogenesispsoriatic arthritistherapy

Identifiers

PMID25231177
PMCPMC4269795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.